- Henlius Trastuzumab Receives FDA Approval in the United States
- Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity
- Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved
- Henlius Forecasts Profit in 2023: Achieving first full year of profitability, and ushering in a new phase of high-quality development
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.94 |
---|---|
High | 17.00 |
Low | 15.82 |
Bid | 16.22 |
Offer | 16.32 |
Previous close | 16.78 |
Average volume | 460.87k |
---|---|
Shares outstanding | 543.49m |
Free float | 81.69m |
P/E (TTM) | 15.06 |
Market cap | 8.87bn HKD |
EPS (TTM) | 1.08 HKD |
Data delayed at least 15 minutes, as of Apr 30 2024 09:08 BST.
More ▼